Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Revenue growth | — | 1.1% | 17.0% | 7.9% | -2.3% | 5.2% | -3.9% | 5.1% |
| Operating income | $1.36B | $2.62B | $1.60B | $1.43B | $307M | $1.49B | $1.29B | $1.56B |
| Operating margin | 76.0% | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| Net income | $1.38B | $2.35B | $975M | $620M | $42.8M | $1.13B | $859M | $771M |
| Net margin | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| EPS (diluted) | — | — | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.62B | $1.67B | $2.03B | $2.02B | $2.14B | $2.99B | $2.77B | $2.49B |
| Share buybacks | $0.00 | $4.27M | $0.00 | $0.00 | $0.00 | $305M | $230M | $1.23B |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.92B | $246M | $1.01B | $1.54B | $1.71B | $477M | $929M | $619M |
| Total assets | — | $12.4B | $16.0B | $17.5B | $16.8B | $16.4B | $18.2B | $19.6B |
| Total liabilities | — | $6.31B | $6.12B | $7.27B | $7.29B | $6.30B | $7.88B | $9.91B |
| Long-term debt | — | $5.96B | $5.82B | $7.10B | $6.12B | $6.14B | $6.61B | $8.57B |
| Shareholders' equity | $4.55B | $6.14B | $9.90B | $10.2B | $9.53B | $10.1B | $10.3B | $9.71B |
| Retained earnings | — | $2.83B | $1.92B | $2.26B | $1.96B | $2.52B | $2.85B | $2.36B |
| Shares (wtd avg diluted) | — | — | 375M | 415M | 438M | 603M | 594M | 564M |
Every figure is extracted from Royalty Pharma plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.